QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 4-biotech-stocks-lifting-off-as-momentum-builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and...

 d-boral-capital-maintains-buy-on-omeros-maintains-36-price-target

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:OMER) with a Buy and maintains $36 price target.

 omeros-published-study-in-blood-advances-shows-narsoplimab-significantly-improves-survival-in-high-risk-ta-tma-patients

Omeros Corporation (NASDAQ:OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of ...

 hims--hers-salesforce-omeros-united-airlines-and-sea-ltd-why-these-5-stocks-are-on-investors-radars-today

Major U.S. indices ended mixed on Wednesday, with the Dow Jones Industrial Average slipping 0.04% to 46,253.31.

 omeros-stock-skyrockets-after-novo-nordisk-strikes-21b-rare-disease-drug-deal

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion ...

 needham-reiterates-hold-on-omerosto-hold

Needham analyst Serge Belanger reiterates Omeros (NASDAQ:OMER) from Hold to Hold.

 wbb-securities-reiterates-strong-buy-on-omeros-maintains-45-price-target

WBB Securities analyst Steve Brozak reiterates Omeros (NASDAQ:OMER) with a Strong Buy and maintains $45 price target.

 hc-wainwright--co-maintains-buy-on-omeros-raises-price-target-to-20

HC Wainwright & Co. analyst Brandon Folkes maintains Omeros (NASDAQ:OMER) with a Buy and raises the price target from $9...

 d-boral-capital-maintains-buy-on-omeros-maintains-36-price-target

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:OMER) with a Buy and maintains $36 price target.

Core News & Articles

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rar...

 d-boral-capital-maintains-buy-on-omeros-maintains-36-price-target

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:OMER) with a Buy and maintains $36 price target.

 omeros-corp-reports-survival-outcomes-with-narsoplimab-in-ta-tma-patients-in-peer-reviewed-study-published-in-american-journal-of-hematology

Omeros Corporation (NASDAQ:OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hemat...

 d-boral-capital-maintains-buy-on-omeros-maintains-36-price-target

D. Boral Capital analyst Jason Kolbert maintains Omeros (NASDAQ:OMER) with a Buy and maintains $36 price target.

 needham-reiterates-hold-on-omerosto-hold

Needham analyst Serge Belanger reiterates Omeros (NASDAQ:OMER) from Hold to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION